Dorothea Rudolph
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dorothea Rudolph has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Gerlach
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
69 shared publications - Norbert Kraut
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
69 shared publications - Jens Quant
Boehringer Ingelheim RCV GmbH & Co KG, 1221 Vienna, Austria
42 shared publications - Alejandro Pérez Pitarch
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
41 shared publications - Andreas Gollner
Boehringer Ingelheim RCV GmbH & Co KG, 1221 Vienna, Austria
41 shared publications - Bojana Golubovic
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
41 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Modulation of p53 target genes in LU0861 tumor-bearing mice treated with brigimadlin.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Modulation of p53 target genes in LU0861 tumor-bearing mice treated with brigimadlin.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 3. Relationship between KRAS wild-type amplification and KRAS oncogenic activity in cell lines. RAS activation signatures (1,3) MSigDB, KrasLA, KRASG13D134, HRAS, MPAS, ras84 and RAS addiction in KRAS wild-type amplified cell lines (relative copy number >7) compared to cell lines with a lower relative copy number (2-7) and KRAS mutated cell lines without KRAS amplification. Enrichment scores were estimated using single sample enrichment (ssGSEA). A one-sided Wilcox-test was used to test for significance between KRAS relative copy number of 2-7 or >7. Adjusted P-values (Benjamini-Hochberg) are displayed.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 3. Relationship between KRAS wild-type amplification and KRAS oncogenic activity in cell lines. RAS activation signatures (1,3) MSigDB, KrasLA, KRASG13D134, HRAS, MPAS, ras84 and RAS addiction in KRAS wild-type amplified cell lines (relative copy number >7) compared to cell lines with a lower relative copy number (2-7) and KRAS mutated cell lines without KRAS amplification. Enrichment scores were estimated using single sample enrichment (ssGSEA). A one-sided Wilcox-test was used to test for significance between KRAS relative copy number of 2-7 or >7. Adjusted P-values (Benjamini-Hochberg) are displayed.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
MDM2 mRNA expression, copy number and brigimadlin in vitro activity in MDM2-amplified cell lines versus MDM2 non-amplified cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
MDM2 mRNA expression, copy number and brigimadlin in vitro activity in MDM2-amplified cell lines versus MDM2 non-amplified cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin in vitro activity in normal cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin in vitro activity in normal cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
IC50 in mouse cell lines with different TP53 status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
IC50 in mouse cell lines with different TP53 status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin dose-dependent regulation of p53 target genes and apoptosis in MDM2-amplified and non-amplified solid tumor cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin dose-dependent regulation of p53 target genes and apoptosis in MDM2-amplified and non-amplified solid tumor cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin PK parameters in SJSA-1 osteosarcoma MDM2-amplified xenograft model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
Brigimadlin PK parameters in SJSA-1 osteosarcoma MDM2-amplified xenograft model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 6: Relationship between KRAS wild-type amplification and KRAS oncogenic activity in TCGA patient data. RAS activation signatures MPAS (3), RAS_addiction and Ras84 (1). Enrichment scores were estimated using single sample enrichment (ssGSEA) in TCGA patient data. A one-sided Wilcox-test was used to test for significance between KRAS relative copy number of 2-7 or >7.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Figure 6: Relationship between KRAS wild-type amplification and KRAS oncogenic activity in TCGA patient data. RAS activation signatures MPAS (3), RAS_addiction and Ras84 (1). Enrichment scores were estimated using single sample enrichment (ssGSEA) in TCGA patient data. A one-sided Wilcox-test was used to test for significance between KRAS relative copy number of 2-7 or >7.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Table 1: PRISM data integrated with omics data from depmap Supplementary Table 2:Top 20 sensitive cell lines (PRISM) Supplementary Table 3:Frequency of KRAS WT AMP in AACR Genie v 15.1 (MSK cohort) Supplementary Table 4: Mututal exclusivity for KRAS WT AMP (results downloaded from AACR Genie v15.1) Supplementary Table 5 IC50 values from CTG assays for KRAS wt amplified cell lines
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification
Supplementary Table 1: PRISM data integrated with omics data from depmap Supplementary Table 2:Top 20 sensitive cell lines (PRISM) Supplementary Table 3:Frequency of KRAS WT AMP in AACR Genie v 15.1 (MSK cohort) Supplementary Table 4: Mututal exclusivity for KRAS WT AMP (results downloaded from AACR Genie v15.1) Supplementary Table 5 IC50 values from CTG assays for KRAS wt amplified cell lines
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
TaqMan primer and probe sets used for RT-PCR.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules
TaqMan primer and probe sets used for RT-PCR.